

Table S19

Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay: Study Design Details and Participant Characteristics for Melbourne Ataxia Speech Treatment as a Treatment Modality

Source	N	Study design	Sex (% female)	Age range (years)	Dysarthria type	Inclusion/exclusion criteria	Inferential statistics	Power analysis	Control group	Baseline data collected	Control intervention	Number of treatment sessions	Mode of treatment delivery	Home exercise plan	Patient-reported outcomes	Treatment effect size
Vogel et al. (2019)	7	Prospective; quasi-experimental	71.40%	NR	NR	Inclusion: <ul style="list-style-type: none"> Genetically-confirmed ARSACS Age > 17 years SARA total score > 3 and speech subscore ≥ 2 	Yes	No	No	Yes – multiple baselines	No	Not reported	Telepractice, individual	Yes	No	No

Note. NR, not reported. ARSACS, autosomal recessive spastic ataxia of Charlevoix-Saguenay. SARA, Scale for the Assessment and Rating of Ataxia.